Pharmaceutical Technology on MSN18h
Servier and Black Diamond sign deal for solid tumours therapy
Servier will be responsible for development and global commercialisation of the therapy for several indications.
BioWorld9d
Korean researchers patent new RAF-1 inhibitors
Scientists at Dongguk University and Korean Research Institute of Bioscience and Biotechnology have disclosed benzofuran compounds targeting heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNPA2B1) ...
Nature1mon
Drug development of MET inhibitors: targeting oncogene addiction and expedience
The MET oncogene encodes the tyrosine kinase receptor for hepatocyte growth factor (HGF), a widely distributed cytokine that is mainly involved in triggering invasive growth. Invasive growth ...
Hosted on MSN11mon
Focusing on oncogenic driver mutations and resistance mechanisms in the treatment of NSCLC
ROS proto-oncogene receptor tyrosine kinase 1 (ROS-1) rearrangements, B-raf proto-oncogene (BRAF) mutations, rearranged during transfection (RET) fusions, Met proto-oncogene (MET) amplification ...